Mirtazapine Viatris

Mirtazapine, the active ingredient in Mirtazapine Viatris, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral dosage form for oral use. It is indicated for the treatment of major depressive disorder in adult patients.

GNH USA supplies Mirtazapine Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine acts on depressive disorders by modulating noradrenergic and serotonergic pathways. - Major depressive disorder: alleviates depressive symptoms and improves mood in adults. - Persistent depressive disorder: helps reduce chronic low mood when prescribed by a clinician. - Treatment‑resistant depression: may be added when first‑line agents are insufficient.

Mirtazapine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Peripheral edema

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Seizures - Severe hypersensitivity reactions (e.g., Stevens‑Johnson syndrome) - Suicidal thoughts or behavior, especially early in treatment - Hepatic dysfunction - Cardiac arrhythmias (QT prolongation)

Before initiating therapy, clinicians should evaluate patient history and monitor for specific concerns. - Assess hepatic and renal function: dose may need adjustment in impairment. - Review concomitant medications: avoid combining with MAO inhibitors. - Monitor weight and metabolic parameters: significant gain may occur. - Observe for emergence of suicidal ideation, particularly in early treatment. - Evaluate for signs of infection or blood dyscrasias. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Mirtazapine can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome. - CNS depressants (e.g., benzodiazepines, opioids): additive sedation. - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase mirtazapine levels.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may exacerbate dry mouth and constipation. - Warfarin: potential alteration of INR, monitor coagulation. - Alcohol: enhances central nervous system depression.